Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research

April 7, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 7, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company's Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Poster presentations include:

**Ganetespib in Breast Cancer (Clinical)**

Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluation first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC).

Presentation: Monday, April 7, 8:00 AM – 12:00 PM PT
Abstract number: 1612
Authors: Petricoin, et al.

**Ganetespib in Lung Cancer (Pre-Clinical)**

The HSP90 inhibitor ganetespib potentiates effect of ionizing radiation in human non-small cell lung cancer

Presentation: Wednesday, April 9, 8:00 AM – 12:00 PM PT
Abstract number: 4894
Authors: Gomez-Casal, et al.

Low dose Ganetespib (STA-9090) enhances radiotherapy effects on lung cancer cells by synergistically altering levels of cell cycle progression proteins

Presentation: Wednesday, April 9, 8:00 AM – 12:00 PM PT
Abstract number: 4902
Authors: Liu, et al.

Screening >60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets

Presentation: Wednesday, April 9, 8:00 AM – 12:00 PM PT
Abstract number: 5450
Authors: Evans, et al.

**Ganetespib in Other Cancers (Pre-Clinical)**

Functional inhibition of HSP90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer

Presentation: Monday, April 7, 8:00 AM – 12:00 PM PT
Abstract number: 1308
Authors: Nagaraju, et al.

The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation

Presentation: Monday, April 7, 1:00 – 5:00 PM PT
Abstract number: LB-140
Authors: Driscoll, et al.

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET driven renal tumor models

Presentation: Tuesday, April 8, 8:00 AM – 12:00 PM PT
Abstract number: 3722
Authors: Miyajima, et al.

HSP90 mediates tumor-associated matrix metalloproteinase 2 and Cathepsin L protease activities in ovarian carcinoma

Presentation: Tuesday, April 8, 1:00 – 5:00 PM PT
Abstract number: 3816
Authors: O’Brien, et al.

**HSP90 as a therapeutic target in colorectal cancer**

Presentation: Tuesday, April 8, 1:00 – 5:00 PM PT
Abstract number: 4221
Authors: Nagaraju, et al.

A multimodality imaging end-point study of everolimus and ganetespib in treatment of pancreatic cancer: A pre-clinical PET/MRI/MRS study
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using its compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements reflect Synta’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Steven Bernitz, 781-541-7250
Senior Vice President, Corporate Development
sbernz@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com
or
Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com